Table 4 Molecular mechanisms of PCAT6 oncogenesis in various cancers
Tumor type | Expression | Molecular mechanisms | References |
|---|---|---|---|
Ovarian cancer | High | Promotes ovarian carcinogenesis and progression by regulating PTEN, while suppression of PTEN expression counteracts the role of PCAT6 in ovarian cell carcinoma | [23] |
Cervical cancer | High | Promotes proliferation and metastasis of cervical cancer cells through regulation of the Wnt/ β-catenin pathway | [26] |
Colon cancer | High | Promote apoptosis in colon cancer cells by regulating the level of anti-apoptotic protein ARC | [46] |
Lung cancer | High | Reduces LATS2 promoter activity by binding to EZH2 leading to H3K27 trimethylation in the LATS2 promoter region, thereby affecting the proliferation and metastasis of non-small cell lung cancer cells | [25] |
High | Influences the biological function of lung cancer cells by affecting the expression of p53 and c-Myc, key proteins that regulate cancer progression | [17] | |
High | Promotes proliferation, migration, and invasion of non-small cell lung cancer cells through regulation of miR-330-5p | [37] | |
Pancreatic ductal carcinoma | High | Promotes the proliferation, migration, and invasion of pancreatic ductal carcinoma cells by secreting miR-185-5p to upregulate the expression of the cancer-related gene CBX2 | [27] |
Osteosarcoma | High | Progression of osteosarcoma is accelerated by regulating the miR-143-3p/ ZEB1 pathway | [23] |
High | Activation of TGF-β pathway promotes osteosarcoma progression by sponging miR-185-5p and upregulating the expression of TGFBR1 and TGFBR2 | [35] | |
High | Promotes proliferation, migration, and invasion of osteosarcoma cells by suppressing p53 and p21 expression through promotion of MDM2 expression | [33] | |
Stomach cancer | High | Promotes proliferation and metastasis of gastric cancer cells by endogenously competing with miR-30 to upregulate MKRN3 expression | [39] |
Bladder cancer | High | Promotes the progression of bladder cancer cells by targeting miR-513a-5p | [43] |
Glioblastoma | High | Upregulates IGF2BP1 expression by miR-513, by forming a PCAT6/ miR-513/ IGF2BP1 positive feedback loop, thus promoting the progression of glioblastoma | [44] |
Gastrointestinal mesenchymal tumor | High | Promotes proliferation of gastrointestinal mesenchymal tumor cells through miR-143-3p upregulation of PRDX5 | [47] |
Breast cancer | High | Promotes TNBC cell proliferation, migration, invasion, EMT, and angiogenesis, as well as tumor growth and metastasis via upregulation of VEGFR2 through sponging miR-4723-5p and recruiting USP14 | [40] |
High | Silencing PCAT6 inhibits the proliferation of triple-negative breast cancer cells and promoted apoptosis by upregulating the expression of miR-185-5p and downregulating the expression of TPD52 | [38] | |
Bile duct cancer | High | Inhibits cell proliferation and invasion by reducing miR-330-5p expression in bile duct cancer cells | [42] |
Pituitary adenoma | High | Promotes pituitary adenoma progression by targeting the miR-139-3p/ BRD4 axis | [45] |